Catalyst Pharmaceuticals Recognized Among Top Growth Companies
Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX), a dedicated biopharmaceutical entity, has proudly announced its ranking as the 304th company in the prestigious 2025 Deloitte Technology Fast 500™. This ranking highlights the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 31st year. Catalyst achieved an impressive revenue growth rate of 249% between fiscal years 2021 and 2024, establishing itself firmly in the competitive landscape of biopharmaceutical innovation.
Leadership and Strategic Vision Driving Success
Rich Daly, President and Chief Executive Officer of Catalyst, attributes this achievement to their best-in-class product portfolio and exceptional commercial capabilities. "We’re proud to be recognized as one of the fastest-growing companies in North America for the second consecutive year, exemplifying the effectiveness of our strategic approach and operational excellence. Our commitment remains focused on delivering sustainable growth while ensuring that we prioritize the needs of patients and the communities we serve," he stated.
Acknowledging the Landscape of Innovation
In reflecting on this year's rankings, Wolfe Tone, US Deloitte Private & Emerging Client Portfolio leader, commented on the unique mix of enduring leadership and breakthrough innovations. Many award winners continue to be influential industry players; however, several newcomers to the list demonstrate significant growth, showcasing the vibrant ecosystem of innovation.
Past Recognition and Future Aspirations
In the previous year, Catalyst secured the 452nd position in the 2024 Deloitte Technology Fast 500 rankings, marking a noteworthy trajectory of growth and expansion. With each passing year, Catalyst not only strives but succeeds in enhancing its position within the biopharmaceutical sector.
Understanding the Deloitte Technology Fast 500
The Deloitte Technology Fast 500 recognizes both private and public companies and is a benchmark for identifying growth in technology and related industries in North America. Winners are selected based on revenue growth percentage from fiscal years 2021 to 2024, with eligibility criteria that include possessing proprietary technology that contributes significantly to revenue and consistent operation for a minimum of four years.
Requirements for Recognition
To qualify for the Technology Fast 500, companies must have a base-year operating revenue of at least $50,000 and current-year revenue of at least $5 million, along with a growth rate of at least 50%. This stringent criterion emphasizes the company’s ability to innovate and adapt in rapidly changing markets.
About Catalyst Pharmaceuticals, Inc.
Catalyst Pharmaceuticals, Inc. (Nasdaq: CPRX) stands out as a committed biopharmaceutical organization, focused on transforming the lives of patients dealing with rare diseases. With a distinguished history of delivering innovative and life-altering therapies, Catalyst is not merely about selling drugs; it encompasses a holistic approach to patient support and care.
Commitment to Patient Care and Accessibility
The company creates an environment where accessibility is paramount. Catalyst ensures that patients can receive the necessary treatments, supported by a comprehensive suite of services that guarantees seamless access to ongoing assistance. Headquarters in Coral Gables, Fla., Catalyst’s strategic approach integrates a robust U.S. presence while continuously exploring avenues for broader global engagement.
Acknowledgments and Recognition
Recently, Catalyst earned a place on the prestigious Forbes 2025 list, recognizing it among America’s Most Successful Mid-Cap Companies while also earning recognition on the 2024 Deloitte Technology Fast 500™ list. These accolades underscore Catalyst's relentless ambition and successful trajectory within the competitive biopharmaceutical industry.
Frequently Asked Questions
What is Catalyst Pharmaceuticals known for?
Catalyst Pharmaceuticals specializes in developing and commercializing innovative treatments for patients with rare and challenging diseases.
How much revenue growth has Catalyst achieved?
Catalyst Pharmaceuticals has reported an impressive revenue growth of 249% from fiscal year 2021 to 2024.
What is the Deloitte Technology Fast 500?
The Deloitte Technology Fast 500 is a ranking that recognizes the fastest-growing companies in the technology and life sciences sectors based on revenue growth.
What criteria must companies meet to qualify for the Fast 500?
To be eligible, companies must have at least $50,000 in base-year revenue, current-year revenue of at least $5 million, and a growth rate of 50% or more over a specified period.
Where is Catalyst Pharmaceuticals located?
The company is headquartered in Coral Gables, Florida, and maintains a strong presence in the U.S. market.
